Loading…
C4 Therapeutics, Inc. is projected to rise to $5.92 by 2027, a +58% move from its current price of $3.74. CCCC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.57 | $3.74 | $3.92 | +0.08% |
| May 30 | $3.50 | $3.75 | $4.00 | +0.15% |
| May 31 | $3.45 | $3.75 | $4.07 | +0.23% |
| Jun 1 | $3.41 | $3.75 | $4.12 | +0.31% |
| Jun 2 | $3.38 | $3.75 | $4.17 | +0.38% |
| Jun 3 | $3.35 | $3.76 | $4.22 | +0.46% |
| Jun 4 | $3.32 | $3.76 | $4.26 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.32 | $3.76 | $4.26 | +0.54% |
| Week 2 | $3.17 | $3.78 | $4.51 | +1.07% |
| Week 3 | $3.06 | $3.80 | $4.72 | +1.61% |
| Week 4 | $2.98 | $3.82 | $4.91 | +2.16% |
| Week 5 | $2.90 | $3.84 | $5.08 | +2.70% |
| Week 6 | $2.84 | $3.86 | $5.24 | +3.25% |
| Week 7 | $2.79 | $3.88 | $5.40 | +3.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co.
Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics, Inc. (CCCC) is a healthcare company operating in the clinical-stage biopharmaceutical space. It is currently priced at $3.56 with a market capitalization of $393.62M and is ranked 3241 by market size among peers.
The stock trades within a 30-day price range of $2.60 to $4.88, reflecting notable volatility and dynamic movement around its current level. The longer-term outlook shows a series of year-by-year price expectations with rising averages and strong return potential, culminating in substantial upside by 2050. The forecasts include a neutral near-term year (2026) and bullish outlooks for subsequent years across a broad price path.
A major floor 54.3% below — a decisive break under it would weaken the trend.
The nearest floor, 31.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 21.0% above — clearing it would confirm fresh momentum.
Key CCCC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CCCC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.52 | Buy | $3.55 | Buy |
| MA 10 | $3.48 | Buy | $3.44 | Buy |
| MA 20 | $3.22 | Buy | $3.28 | Buy |
| MA 50 | $2.94 | Buy | $3.02 | Buy |
| MA 100 | $2.62 | Buy | $2.79 | Buy |
| MA 200 | $2.55 | Buy | $2.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.75 | Neutral |
| Stoch RSI (14) | 65.44 | Neutral |
| CCI (20) | 127.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 26.78 | Buy |
| Bollinger %B (20,2) | 0.91 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.75 | Buy |
| Awesome (5,34) | 0.44 | Buy |
| Ultimate (7,14,28) | 61.31 | Neutral |
| Momentum (10) | 0.57 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 3.63 | Buy |
| ADX (14) | 17.55 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is bullish, with RSI14 at 60, suggesting room to move higher within momentum. The stock’s simple moving averages sit at $2.91 (SMA50) and $2.53 (SMA200), indicating near-term support around the mid-$2s and a gradually rising trend.
Key supports and resistances are pegged at $2.56 and $3.68, respectively, guiding trading ranges. The 30-day range is $2.60 to $4.88, showing a wide swing within the month. Annualized volatility stands at 90%, underscoring the potential for rapid price moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.71 | $3.74 | $6.38 | 0% | Neutral | |
| $4.36 | $5.92 | $8.66 | +58% | Bullish | |
| $5.72 | $8.17 | $12.65 | +119% | Bullish | |
| $6.44 | $9.61 | $15.53 | +157% | Bullish | |
| $5.52 | $8.57 | $14.36 | +129% | Bullish | |
| $6.09 | $9.80 | $16.95 | +162% | Bullish | |
| $6.80 | $11.33 | $20.15 | +203% | Bullish | |
| $8.00 | $13.81 | $25.17 | +269% | Bullish | |
| $10.46 | $18.63 | $34.75 | +398% | Bullish | |
| $10.26 | $18.86 | $35.94 | +404% | Bullish | |
| $15.49 | $33.12 | $68.86 | +785% | Bullish | |
| $24.89 | $55.31 | $127.21 | +13.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.71 | $3.74 | $4.42 | +0.00% |
| June 2026 | $3.10 | $3.70 | $4.56 | -1.02% |
| July 2026 | $3.31 | $4.01 | $5.06 | +8.31% |
| August 2026 | $3.60 | $4.41 | $5.66 | +10.02% |
| September 2026 | $3.57 | $4.42 | $5.75 | +0.13% |
| October 2026 | $3.52 | $4.39 | $5.79 | -0.54% |
| November 2026 | $3.70 | $4.66 | $6.20 | +6.00% |
| December 2026 | $3.74 | $4.74 | $6.38 | +1.75% |
Click any year to see its month-by-month CCCC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CCCC is projected to trade between $1.71 and $6.38, averaging $3.74 — a potential gain of 0% from today's $3.74. A consolidation phase looks the most probable path here.
C4 Therapeutics, Inc.'s 2027 outlook centres on $5.92, within a $4.36 to $8.66 range. That is up +58% on the projected 2026 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2028, CCCC could reach as high as $12.65, with a base case around $8.17 and support toward $5.72 — roughly +119% from $3.74. Buyers look set to stay in control over this stretch.
Expect CCCC to range from $6.44 to $15.53 through 2029. The $9.61 average target implies a +157% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The CCCC price prediction for 2030 points to an average of $8.57 (low $5.52, high $14.36) — a potential gain of +129% on today's $3.74. Buyers look set to stay in control over this stretch.
In 2031, CCCC is projected to trade between $6.09 and $16.95, averaging $9.80 — a potential gain of +162% from today's $3.74. That is up +14% on the projected 2030 average. Momentum favours further upside here.
C4 Therapeutics, Inc.'s 2032 outlook centres on $11.33, within a $6.80 to $20.15 range. That is up +16% on the projected 2031 average. That marks a +203% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CCCC could reach as high as $25.17, with a base case around $13.81 and support toward $8.00 — roughly +269% from $3.74. Momentum favours further upside here.
Expect CCCC to range from $10.46 to $34.75 through 2034. The $18.63 average target implies a +398% move from current prices. That is up +35% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CCCC price prediction for 2035 points to an average of $18.86 (low $10.26, high $35.94) — a potential gain of +404% on today's $3.74. Momentum favours further upside here.
In 2040, CCCC is projected to trade between $15.49 and $68.86, averaging $33.12 — a potential gain of +785% from today's $3.74. That is up +76% on the projected 2035 average. Buyers look set to stay in control over this stretch.
C4 Therapeutics, Inc.'s 2050 outlook centres on $55.31, within a $24.89 to $127.21 range. That is up +67% on the projected 2040 average. That marks a +13.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CCCC today (≈ 267.379679 CCCC) could be worth
$14,788.16
+$13,788.16 (+1379%) by 2050 · US Dollar
Based on the average projected CCCC price of $55.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CCCCwould be worth at today's price.
$1,000 invested in CCCC on May 27, 2025 (≈ 769.230797 CCCC) would be worth
$2,876.92
+$1,876.92 (+187.7%) today · 2.88× · US Dollar
Based on a CCCC entry price of $1.3 vs. today's $3.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.28 | $1,140.24 | +14.0% |
| 1 month ago | $2.83 | $1,321.55 | +32.2% |
| 3 months ago | $2.78 | $1,345.32 | +34.5% |
| 6 months ago | $2.71 | $1,380.07 | +38.0% |
| 1 year ago | $1.3 | $2,876.92 | +187.7% |
| All time (5.0y) ago | $37.46 | $99.84 | -90.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CCCC forecast.
Our base-case forecast reaches $7.50 around 2028.
Implied market cap at $7.50: $829.25M
The multi-year forecast shows a bullish trajectory with rising average prices and notable upside potential. The 2026 average is $3.56 with a neutral sentiment, while 2027–2050 exhibits a bullish stance and escalating ROIs.
From 2027 to 2035, the model projects rising averages: 2027 $5.47, 2028 $7.58, 2029 $8.70, 2030 $7.68, 2031 $8.80, 2032 $9.89, 2033 $11.85, 2034 $16.19, and 2035 $16.21, with ROIs ranging from 53.5% to 355.4% and bullish sentiment.
The forecast continues to climb toward 2040 and 2050, with 2040 average $27.99 (ROI 686.2%) and 2050 average $44.76 (ROI 1157.3%), both with bullish sentiment. The maximum projected prices reach $12.91 in 2030, $58.48 in 2040, and $102.95 in 2050, illustrating substantial upside but recognizing the estimates are not guarantees and carry uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.68 with a minimum of $4.93 and a maximum of $12.91, and a projected ROI of 115.6% with bullish sentiment.
The forecast turns bullish from 2027 onward, with rising average prices and substantial ROIs (up to 1157.3% by 2050) but includes neutral sentiment in 2026 and notes that these are estimates, not guarantees.
The 2050 maximum forecast is $102.95, indicating a potential to reach around that level by 2050 according to the projections.
Current price is $3.56 per share and market cap is $393.62M.
The 30-day range is $2.60 to $4.88.
C4 Therapeutics, Inc. Community Discussion
0Share your C4 Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.